HEALTHCARE · BIOTECHNOLOGY

Biomarin Pharmaceutical Inc (BMRN) Stock Price, Analysis & Trade Signals

$66.12+1.05 (+1.61%)

BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for ph…

Market Cap
$12.80B
CEO
Alexander Hardy
Employees
3,221
IPO Date
1999-07-26
Website
www.biomarin.com

Tabs · Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics